Repaglinide re-branded

30 November 2006

Daiichi Sankyo has acquired the sales and marketing rights for repaglinide in the UK. Repaglinide will be launched using the brand name Prandin. The existing brand of repaglinide, NovoNorm, will remain available for the next few months. Next year, Novonorm will be discontinued and repaglinide will only be marketed as Prandin.

The licence for Prandin is identical to that for Novonorm. Both products are indicated for the treatment of type 2 diabetes with hyperglycaemia uncontrolled by diet, weight reduction and exercise. They are also indicated in combination with metformin in type 2 diabetes not satisfactorily controlled on metformin alone.

The recommended starting dose is 0.5mg, followed by dose titration at one- to two-weekly intervals according to response.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...